Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference

New York — February 8, 2018 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Rett syndrome and other central nervous system (CNS) diseases, announced today that its President & Chief Executive Officer, Christopher U. Missling,…

Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results

Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK – February 7, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported…

Financial

Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical Programs and Corporate Highlights on Wednesday, February 7, 2018

Conference Call and Webcast To be Held Wednesday, February 7, 2018 at 4:30pm Eastern Time   NEW YORK, NY – February 5, 2017 – Anavex Life Sciences Corp., (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including Alzheimer’s disease, other central nervous…